Rice Hall James & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rice Hall James & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,933	Closed	-$2.5M	–	275
2023 Q1	$2.5M	Sell	22,933 -229	-1%	-$25.3K	0.14%	161
2022 Q4	$2.64M	Buy	23,162 +164	+0.7%	+$13.6K	0.15%	160
2022 Q3	$1.42M	Buy	+22,998	New	+$1.61M	0.08%	214
2015 Q4	–	Sell	-427,163	Closed	-$8.47M	–	322
2015 Q3	$8.47M	Buy	427,163 +502	+0.1%	+$15.9K	0.55%	60
2015 Q2	$14.8M	Sell	426,661 -238,243	-36%	-$7.27M	0.86%	47
2015 Q1	$17.3M	Buy	+664,904	New	+$12.2M	1%	34

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rice Hall James & Associates's HZNP Position: Q2 2023 in Review

Rice Hall James & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 22,933 shares — an estimated $2.5M sold.

Rice Hall James & Associates first reported a position in HZNP in Q1 2015 and held it in 6 quarters. The position peaked at $17.3M in Q1 2015. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Rice Hall James & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Rice Hall James & Associates sold 22,933 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.5M.
Rice Hall James & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 6 quarters.
Rice Hall James & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.3M in Q1 2015.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Rice Hall James & Associates's 13F filing for Q2 2023, filed 24 Jul 2023.